益生菌在改善运动功能和缓解帕金森病中便秘的有效性:一个随机对照试验
Nasibeh Ghalandari1, Farhad Assarzadegan2, Seyed Amir Hassan Habibi3
1Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iranian journal of pharmaceutical research : IJPR
|December 20, 2023
概括
多菌株益生菌在八周内显著改善了帕金森病 (PD) 患者的便秘症状,包括肠道运动频率和便一致性. 运动功能没有受到影响,这表明益生菌可能有助于在PD中管理胃肠道问题.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 帕金森病 (PD) 是一种常见的神经退行性疾病.
- 肠道失调症越来越多地与PD病变和胃肠道问题 (如便秘) 有关.
- 便秘是PD患者常见的和令人虚弱的并发症.
研究的目的:
- 研究多菌株益生菌在减轻帕金森病患者便秘的疗效.
- 评估益生菌对PD患者运动功能的影响.
- 评估排便频率的变化,便的一致性和药的使用.
主要方法:
- 一个盲目的随机对照试验 (RCT),涉及27名患有便秘的PD患者 (ROME IV标准).
- 干预组接受了多菌株益生菌;安慰剂组接受了安慰剂八周.
- 主要结果:排便频率. 二次结果:药的使用,完全疏散的感觉,布里斯托尔便尺度和统一的帕金森病评级尺度 (UPDRS).
主要成果:
- 与安慰剂相比,益生菌组的肠道排便频率显著增加 (P=0.02) 和便一致性改善 (P=0.04).
- 组内分析显示,两组的便一致性都显著改善,但只有益生菌组在便频率和完全疏散的感觉上有显著改善.
- 两组之间没有观察到运动功能 (UPDRS分数) 或药使用的显著差异.
结论:
- 多菌株益生菌可以有效地改善帕金森病患者的便秘症状 (频率,一致性,完全疏散).
- 在为期八周的研究期间,益生菌对运动功能没有显著影响.
- 建议进行进一步的研究,以探索益生菌对PD患者的长期影响.
相关概念视频
01:24Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
01:15Parkinson's Disease: Overview
554
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
554
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
332
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
332
01:21Drugs for Treatment of Constipation-Predominant IBS
176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
264
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
264
01:20Drugs Affecting GI Tract Motility: Other Laxatives
227
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
227